Guardian Pharmacy Services, Inc. (GRDN) stock analysis
Close on Nov 11, 2026Market cap $3.17BP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed9 of 30 checks passed
Guardian Pharmacy Services passes 9 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 2/6
- Past performance
- 1/6
- Financial health
- 6/6
- Dividend
- 0/6
What stands out
No debt
Guardian Pharmacy Services has no borrowings on its latest balance sheet.
Interest well covered
Operating income covers interest expense 145.3 times.
Debt covered by cash flow
There is no debt to cover.
Low bankruptcy risk
The Altman Z-score is 13.18; above 3 is the safe zone and below 1.8 the distress zone.
What to watch
Margin of safety under 20%
The price is 157% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $49.98 is above our fair value estimate of $19.44.
P/S above the industry
Guardian Pharmacy Services's price-to-sales of 2.17 is above the Miscellaneous Retail median of 0.62 (book value is negative, so we use sales).
Growing slower than the industry
Revenue grew 4.9% over the last twelve months; the Miscellaneous Retail median is 5.9%.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/S above the industry
Guardian Pharmacy Services's price-to-sales of 2.17 is above the Miscellaneous Retail median of 0.62 (book value is negative, so we use sales).
Trading above fair value
The share price of $49.98 is above our fair value estimate of $19.44.
Margin of safety under 20%
The price is 157% above fair value, so there is no margin of safety.
Growth2/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew 4.9% over the last twelve months; the Miscellaneous Retail median is 5.9%.
Guidance raised
Guardian Pharmacy Services raised its FY 2026 Revenue outlook on Aug 6, 2026.
Gross margin improving
Gross margin was 22.4% over the last twelve months, against 19.7% a year earlier.
Past performance1/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin above the industry
Guardian Pharmacy Services's net margin of 5.1% is above the Miscellaneous Retail median of -0.3%.
Financial health6/6
No debt
Guardian Pharmacy Services has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
Operating income covers interest expense 145.3 times.
Short-term assets cover short-term debts
Current assets are 1.65 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 13.18; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Guardian Pharmacy Services has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$19.44
The share price is 157% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| EV/EBITDA | 10.8× | – | 10.8× | $21.90 | 70% |
| Earnings power | 7.7% cost of equity | – | – | $13.69 | 30% |
| Fair value | $19.44 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $20.76M
- Value traded per 1% price move
- $10.39M
Downside
Low risk
- Typical loss in a bad month
- 11.8%
- Volatility (annualized)
- 43%
- Sharpe ratio, 1 year
- 1.47
- Beta to the S&P 500 (5Y)
- 0.56
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2022 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.9% | – | – | – | |
| Gross profit | +19.8% | – | – | – | |
| Free cash flow | +100.8% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2022 | FY2022 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | – | 13.4% | |
| Current ratio | – | – | 1.38 | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | – | – | 109.3× | |
| Inventory turnover | – | – | 27.6× | |
| Capex to revenue | – | – | 0.9% |
Cash use needs five years of cash flow figures
Guardian Pharmacy Services does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$49.22M
- Cash generatingOperating cash flow above zero$100.26M
- Return on assets improvedROA up on the prior year-40.6% → 15.3%
- Earnings backed by cashOperating cash flow above net income$100.26M vs $49.22M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose1.05 → 1.38
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year19.89% → 20.21%
- More efficientAsset turnover rose4.53 → 4.52
See a number that looks wrong?